Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he described as “the beginning of a long cycle,” supported by recent launches, a broadening pipeline, and continued operating discipline. Dickinson said Gilead had an “extraordinary 2025” across its base business, clinical results and commercial execution, highlighting two major product launches: YEZTUGO, its once-every-six-month subcutaneous HIV prevention medicine, and LIVDELZI, which is in its first full year on the market for primary biliary cholangitis (PBC). He emphasized “very strong operating expense control,” “significant growth in EPS,” and what he called the strongest pipeline in the company's history. Arcellx acquisition: “best-in-class” BCMA cell therapy ? Amazon Is Rising While the Market Falls—Here's Why These 3 Cash Flow Machines Provide Stability in Uncertain Markets Dickinson discussed Gilead's decision to acqui
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast CancerPR Web
- 3 Cash-Flow Machines Investors May Want Heading Into 2026 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]Yahoo! Finance
- Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/16/26 - Form 144
- GILD's page on the SEC website